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October 12, 2010:1352–6Furthermore, a review of current literature suggests that the
pproach of using only effect sizes when comparing the utility of
isk factors may be obsolete—particularly in light of more efficient
tatistical approaches such as net reclassification index and incre-
ental discrimination index (2,3)—the techniques that enable
omparisons based on number of subjects correctly allocated with
he enhanced risk or not.
However, we agree that despite these further analyses, the eventual
nterpretation may remain unchanged, as evidenced by findings of a
ecent study (4) among 19,000 hypertensive patients, where there
as an absence of any synergy among the individual components of
S on the risk of coronary outcomes associated with MS. However,
n that study, the risk of stroke and all-cause mortality associated with
S, independent of its components, was found to be significant. We
elieve these apparent contradictions in the current literature are likely
o be minimized by interrogating prospective data, to evaluate
hether the risk of myocardial infarction (both in terms of magnitude
nd the number of patients correctly identified) is more closely
ssociated with MS or with the presence of each of the individual risk
actors, separately and in combination.
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eply
rs. Gupta and Poulter raise an interesting point about our study (1)
nd about estimating the risk of myocardial infarction (MI) associated
ith metabolic syndrome (MS), after adjusting for all its individual
omponents (as continuous variables). The idea of controlling for all
omponents and MS simultaneously to assess each of the effects
omparatively seems intuitive. However, there are statistical assump-
ions in constructing such a model. Controlling for component factors
hat were used to define MS would likely substantially alter the
ssociation between MS and MI risk. Indeed, when adjusting for all
f the individual MS components, the odds of MS on MI risk is 1
odds ratio: 0.79; 95% confidence interval: 0.68 to 0.91); however, theffects of diabetes mellitus (odds ratio: 2.52; 95% confidence interval:
.24 to 2.83) and hypertension (odds ratio: 2.22; 95% confidence
nterval: 2.05 to 2.39) remain robust after simultaneous adjustment.
rior investigations have used a similar approach to that of our study
n assessing the effects of MS and component factors (2,3).
We agree that alternative analytical approaches may be used to
etermine the agreement between MS and component factors clas-
ification versus MI (e.g., net reclassification). However, this approach
s usually applied to prospective cohort data, and not to retrospective
ase-control data. Nonetheless, as the investigators recognize, the
eneral pattern of results and eventual interpretation is unlikely to
hange. Moreover, an important advantage of estimating the effect
ize is that it may be used to estimate population attributable risk
PAR), an approach used previously in the first INTERHEART
tudy (a global case-control study of risk factors for acute myocardial
nfarction) paper, which showed that 90% of risk of MI is explained
y 9 modifiable risk factors (4). An assessment of the PAR of MS on
I is particularly important in the current study, since the use of a
ichotomous definition of MS based on 3 risk factors leads to a
ubstantially lower prevalence of MS than its component factors (e.g.,
0% for MS compared with 19.6% for diabetes and 23.4% for
ypertension). This finding partly explains our observation that the
AR of MS is substantially lower than the PAR of several component
actors considered separately, including diabetes and hypertension,
nd indicates that MS accounts for a smaller number of MI cases in
population compared with several of its constituent components.
hus, our findings highlight an important limitation of MS diagnosis.
We also agree that a cohort study might provide more rigorous
ata. However, an important strength of the INTERHEART study
s that it is a large international study of 52 countries using a stan-
ardized protocol, and it is the first large study to show that the risk
f MI associated with MS is qualitatively similar across sex, global
egions, and ethnic groups. A cohort study with similar objectives
ould require an enormous sample size and 2 decades of follow-up.
lthough not impossible, such a study would be extremely costly to
onduct.
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